CH | EN

News

News Center

Company News

Industry News

Science Popularization

Video

Clinical Recruitment: 45 Patients with Ischemic Stroke

2024-02-26

Currently, China's first Phase I/IIa clinical trial (ASSIST) using imported stem cells to treat ischemic stroke—led by Jiuzhitang Maker—is underway. ， We are now recruiting 45 patients with ischemic stroke to voluntarily participate in a Phase IIa clinical trial.

Project Overview

This is a Phase II, multicenter, double-blind, randomized, placebo-controlled study (ASSIST) evaluating the safety, tolerability, and preliminary efficacy of a single injection of ischemia-tolerant human allogeneic bone marrow mesenchymal stem cells (itMSCs) in patients with ischemic stroke.

The study has been approved by the National Medical Products Administration and the ethics committees of all participating research centers. It is being conducted at three hospitals in Beijing and plans to enroll a total of 45 patients with ischemic stroke.

Recruitment Requirements

This study aims to evaluate the safety, tolerability, and clinical efficacy of ischemia-tolerant allogeneic bone marrow mesenchymal stem cells in treating patients with ischemic stroke.

Men and women aged 18 and older;

The medical history reveals that the most recent clinical diagnosis of ischemic stroke occurred more than 6 months ago.

There is severe neurological impairment, requiring assistance from others to walk or making it impossible to independently perform everyday activities.

Other qualified physicians, based on their comprehensive assessment, have determined that you meet the study’s eligibility criteria—and provided the participant has given informed consent—you’re welcome to choose to participate in this research.

After screening, if you meet the criteria and are eligible to participate in the study, the study treatment medication and related examination costs will be covered by the sponsor.

Number of positions available: 45 individuals

Center List and Contacts

For detailed information about the trial, please contact the study doctor between 8:30 a.m. and 5:30 p.m. on weekdays.

Beijing Tiantan Hospital Affiliated to Capital Medical University

Teacher Lü, 13683321406

Beijing Tongren Hospital, Affiliated to Capital Medical University

Teacher, 18801118775

Peking University Third Hospital

Teacher Song, 18001267591

You're invited to the Seminar on Cell-Based Drug Development and Regulatory Submission

Xiong'an officially released! New area-based bio-companies and medical institutions are encouraged to apply for cutting-edge medical technology research projects aimed at conducting clinical studies involving stem cells, leveraging their own technological capabilities.

Here is the title—h1 placeholder text

Online Message

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Business license